A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells

作者：Fernando Joan; Malfettone Andrea; Cepeda Edgar B; Vilarrasa Blasi Roser; Bertran Esther; Raimondi Giulia; Fabra Angels; Alvarez Barrientos Alberto; Fernandez Salguero Pedro; Fernandez Rodriguez Conrado M; Giannelli Gianluigi; Sancho Patricia; Fabregat Isabel^*

来源：International Journal of Cancer, 2015, 136(4): E161-E172.

DOI：10.1002/ijc.29097

• sorafenib
• liver cancer
• CD44
• EMT
• TGF-beta

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of hepatocellular carcinoma (HCC). However, response differs among patients and effectiveness only implies a delay. We have recently described that sorafenib sensitizes HCC cells to apoptosis. In this work, we have explored the response to this drug of six different liver tumor cell lines to define a phenotypic signature that may predict lack of response in HCC patients. Results have indicated that liver tumor cells that show a mesenchymal-like phenotype, resistance to the suppressor effects of transforming growth factor beta (TGF-) and high expression of the stem cell marker CD44 were refractory to sorafenib-induced cell death in in vitro studies, which correlated with lack of response to sorafenib in nude mice xenograft models of human HCC. In contrast, epithelial-like cells expressing the stem-related proteins EpCAM or CD133 were sensitive to sorafenib-induced apoptosis both in vitro and in vivo. A cross-talk between the TGF- pathway and the acquisition of a mesenchymal-like phenotype with up-regulation of CD44 expression was found in the HCC cell lines. Targeted CD44 knock-down in the mesenchymal-like cells indicated that CD44 plays an active role in protecting HCC cells from sorafenib-induced apoptosis. However, CD44 effect requires a TGF--induced mesenchymal background, since the only overexpression of CD44 in epithelial-like HCC cells is not sufficient to impair sorafenib-induced cell death. In conclusion, a mesenchymal profile and expression of CD44, linked to activation of the TGF- pathway, may predict lack of response to sorafenib in HCC patients.
What's new? Sorafenib remains the standard of care for advanced hepatocellular carcinoma (HCC), despite marked variability in patient response. According to this study, a lack of response to sorafenib may be predicted by certain phenotypic signatures of liver tumor cells, specifically activation of the TGF-ss pathway, a mesenchymal phenotype, and expression of CD44. By contrast, sensitivity to sorafenib-induced apoptosis is associated with expression of the stem-related proteins EpCAM or CD133 in epithelial-like cells and knockdown of CD44 in mesenchymal-like cells. The findings suggest that CD44 targeting could be a valuable strategy to deploy in combination with sorafenib therapy.

• 出版日期2015-2-15